Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2015

01-10-2015 | Breast Oncology

Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base

Authors: Meghan R. Flanagan, MD, MPH, Mara H. Rendi, MD, PhD, Vijayakrishna K. Gadi, MD, PhD, Kristine E. Calhoun, MD, Kenneth W. Gow, MD, Sara H. Javid, MD

Published in: Annals of Surgical Oncology | Issue 10/2015

Login to get access

Abstract

Background

Adjuvant endocrine therapy (AET) has been shown to reduce the risk of second breast cancer events in women with ductal carcinoma in situ (DCIS). There is no population-level evaluation of AET use in DCIS patients after standardized reporting of estrogen receptor (ER) status in cancer registries in 2004.

Methods

We conducted a retrospective cohort study of women with DCIS in the National Cancer Data Base between 2005 and 2012. Patient, tumor, and treatment characteristics as well as temporal trends associated with receipt of AET were evaluated by generalized linear regression.

Results

Among 206,255 DCIS patients, 36.5 % received AET. Fewer than half of ER-positive patients (n = 62,146, 46.4 %) received AET, with a modest but significant increase over time (43.6 % in 2005 to 47.5 % in 2012; unadjusted p trend <0.001). AET decreased among ER-negative patients (8.9–6.5 %, p trend <0.001) over the same time period. On multivariate analysis, younger (<40 years) and older (≥70 years) women were less likely to receive AET than 50- to 59-year-old women (<40 years: relative risk 0.86, 95 % confidence interval 0.82–0.89; ≥70 years: relative risk 0.79, 95 % confidence interval 0.77–0.81). ER-positive status conferred a 6.15-fold higher likelihood of receiving AET compared to ER-negative status (95 % confidence interval 5.81–6.50). Women who underwent breast-conserving surgery (BCS) with adjuvant radiotherapy were most likely to receive AET.

Conclusions

Receipt of AET is relatively low in the group of women most likely to benefit from its use, namely ER-positive patients who underwent BCS. Significant variation exists with respect to patient, tumor, site, and treatment factors. More tolerable drugs or clearer guideline recommendations may increase use.
Literature
1.
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.CrossRefPubMed
2.
Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.PubMedCentralCrossRefPubMed
3.
Wehner P, Lagios MD, Silverstein MJ. DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) guidelines. Ann Surg Oncol. 2013;20:3175–9.CrossRefPubMed
4.
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.PubMedCentralCrossRefPubMed
5.
Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2006;192:416–9.CrossRefPubMed
6.
Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 2011;129:929–38.CrossRefPubMed
7.
Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.CrossRefPubMed
8.
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.CrossRefPubMed
9.
10.
Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.CrossRefPubMed
11.
Ceilley E, Jagsi R, Goldberg S, Kachnic L, Powell S, Taghian A. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer. 2004;101:1958–67.PubMed
12.
Livaudais JC, Hwang ES, Karliner L, et al. Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health. 2012;21:35–42.CrossRef
13.
Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg. 2005;201:688–94.CrossRefPubMed
14.
Yen TWF, Kuerer HM, Ottesen RA, et al. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol. 2007;25:3251–8.CrossRefPubMed
15.
Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer. 2006;106:2113–8.CrossRefPubMed
16.
Virnig BA, Torchia MT, Jarosek SL, Durham S, Tuttle TM. Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer. Data Points 14. Rockville: Agency for Healthcare Research and Quality; 2011.
17.
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCentralCrossRefPubMed
18.
Schafer J. Analysis of incomplete multivariate data. London: Chapman and Hall; 1997.CrossRef
19.
20.
McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940–3.CrossRefPubMed
21.
Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor–positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30:1268–73.PubMedCentralCrossRefPubMed
22.
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.CrossRefPubMed
23.
Jackson LC, Camacho F, Levine EA, Anderson RT, Stewart JH. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. Am J Surg. 2008;195:164–9.CrossRefPubMed
24.
Feigelson HS, Carroll NM, Weinmann S, et al. Treatment patterns for ductal carcinoma in situ from 2000–2010 across six integrated health plans. Springerplus. 2015;4:24.PubMedCentralCrossRefPubMed
25.
Haque R, Achacoso NS, Fletcher SW, et al. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010;16:351–60.PubMedCentralPubMed
26.
Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986;57:197–208.CrossRefPubMed
27.
Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137–46.CrossRefPubMed
28.
Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.CrossRefPubMed
29.
Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300.CrossRefPubMed
30.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.CrossRef
31.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefPubMed
32.
Javid SH, He H, Korde LA, Flum DR, Anderson BO. Predictors and outcomes of completion axillary node dissection among older breast cancer patients. Ann Surg Oncol. 2014;21:2172–80.CrossRefPubMed
33.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.CrossRefPubMed
34.
Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.CrossRefPubMed
35.
Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference Statement. Diagnosis and management of ductal carcinoma in situ, September 22–24, 2009. J Natl Cancer Inst. 2010;102:161–9.CrossRefPubMed
36.
Friese CR, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013;138:931–9.PubMedCentralCrossRefPubMed
Metadata
Title
Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base
Authors
Meghan R. Flanagan, MD, MPH
Mara H. Rendi, MD, PhD
Vijayakrishna K. Gadi, MD, PhD
Kristine E. Calhoun, MD
Kenneth W. Gow, MD
Sara H. Javid, MD
Publication date
01-10-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 10/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4668-z

Other articles of this Issue 10/2015

Annals of Surgical Oncology 10/2015 Go to the issue

Breast Oncology

Chemoprevention for Breast Cancer

Breast Oncology

Contemporary Challenges in Genetic Testing for Breast Cancer: A Collaboration Opportunity for Genetic Counselors and Breast Surgeons

Breast Oncology

Normal Axillary Ultrasound Excludes Heavy Nodal Disease Burden in Patients with Breast Cancer

Breast Oncology

Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple–Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review

Breast Oncology

Treatment and Prognosis of Rare Breast Cancers

Breast Oncology

Starting a Radioactive Seed Localization Program